Business Wire

Guidewire Reimagines Insurance Core Platforms with Aspen Release

16.6.2020 15:55:00 EEST | Business Wire | Press release

Share

Guidewire Software, Inc. (NYSE: GWRE), the platform P&C insurers trust to engage, innovate, and grow efficiently, today announced the launch of Aspen 2020.1H, featuring the first cloud-optimized release of Guidewire InsuranceSuite, and additional enhancements to Guidewire Analytics and Guidewire for Salesforce. Aspen1 extends support for insurers’ imperatives to unlock business and IT agility for accelerated product launches, personalized digital experiences, and embedded analytics throughout the insurance lifecycle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005534/en/

Insurers around the world are focused on digitally engaging with customers and agents and making insurance more convenient. They need to innovate and launch new insurance products quickly and iterate them in market. Insurers must also grow their business efficiently by continuously measuring performance and testing process improvements. These goals typically require complex IT projects with insurers facing execution challenges due to a lack of IT agility. With Aspen, Guidewire delivers a cloud-optimized platform that delivers the agility insurers need to meet their business imperatives.

“The P&C insurance industry continues to evolve rapidly, and insurers, now more than ever, need the ability to quickly react and respond to market changes and needs,” said Karlyn Carnahan, head of Celent’s Property and Casualty practice for the Americas. “Cloud-optimized, digital-first platforms are the way of the future and will empower insurers to be competitive, reduce costs, and provide high levels of customer service, while increasing flexibility and agility.”

“For more than 18 years we have been dedicated to addressing the core system requirements of the P&C industry and today we are excited to announce a new approach,” said Mike Rosenbaum, chief executive officer, Guidewire. “Aspen is a significant milestone in our cloud journey and is arguably the most pivotal release in Guidewire’s history. It marks a redefinition in what we mean when we say core platform. Insurers expect that a core platform should do more than just run their core business processes. It also needs to be inherently connected to digital interfaces, take advantage of analytics capabilities, and be able to integrate data from any source. This is why we are unifying digital, analytics, and the core into one platform delivered in Guidewire Cloud.”

“Aspen is our first bi-annual cloud-optimized release that will bring customers even more IT agility, allowing them to get more value from their investment by laying the foundation for continuous improvement and future innovations,” said Diego Devalle, global head, Product and Engineering, Guidewire. “Beginning with the rating, rules, and data cloud-native services found in Aspen and continuing with subsequent releases, we will deliver a new generation of products that leverages cloud services architecture, and will continue building an open platform leveraging APIs.”

Aspen has been designed to bring agility to P&C insurers like never before to support their key imperatives:

Innovate

Aspen helps insurers create new products in days not months, analyze performance, and iterate at the speed of the market with reduced reliance on IT. Insurers can:

  • Accelerate product launches with Advanced Product Designer, a business-user friendly tool with visual, low-code configuration, while streamlining collaboration and design efforts.
  • With Guidewire Cloud, IT can stay current forever, rather than having to implement costly infrastructure upgrades. With fast cadence upgrades, IT will have access to two updates a year, allowing insurers to frequently consume new innovation and product capabilities.
  • Embrace and conquer new and evolving risks through Cyence risk insights that leverage petabytes of data on behavioral, social, and environmental signals so insurers can differentiate risk, automate underwriting, and make smarter pricing and risk selection decisions.

Engage

The release enables insurers to automatically create digital experiences that can easily be customized to serve all their customer segments. It allows them to:

  • Personalize digital experiences with the auto-generation of digital screens directly in PolicyCenter leveraging Advanced Product Designer for visual product definitions to help insurers best serve all of their customer segments.
  • Enable a unified and holistic customer view with Guidewire for Salesforce due to its ability to power insight-driven interactions with claims and policy service data, auto-generate quote and buy experiences, and allow sales and service teams to sell and service policies.
  • Deploy Cyence for Personal Cyber for on-demand, personalized cybersecurity assessments that include custom remediation recommendations to help users reduce their cyber risk.

Grow Efficiently

Aspen empowers insurers to leverage Guidewire Analytics powered by Guidewire Data Platform and Cyence to uncover hidden opportunities and write profitable business with a seamless path from data to value. The release enables insurers to:

  • Obtain data (including all intra-daily changes) from core systems in real-time via Cloud Data Access, a service of Guidewire Data Platform, and gain a competitive edge through Cyence data listening, to support their enterprise-wide data and analytics strategy.
  • Leverage embedded predictive analytics in core workflows to optimize operations and improve underwriting profitability.

About Guidewire

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. ​We combine digital, core, analytics, and AI to deliver our platform as a cloud service. As of the end of our fiscal year 2019, more than 380 insurers, from new ventures to the largest and most complex in the world, run on Guidewire. ​

As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.

For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC.

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.

All products mentioned in this announcement are Guidewire products.

1Not all products are available in every geography or to self-managed customers. Guidewire customers can get more information from their Account Executive.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the future release schedule for Guidewire InsuranceSuite, Guidewire’s commitment to cloud services architecture for future products development, and general availability of products mentioned in this release. Forward-looking statements include those preceded by, followed by or that include the words “will,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “plans,” “estimates,” “targets,” “projects,” “intends” or similar expressions. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the impact of the COVID-19 pandemic on our employees and our business and the businesses of our customers, system integrator partners, and vendors; our reliance on sales to and renewals from a relatively small number of large customers for a substantial portion of our revenue; our ability to successfully manage any changes to our business model, including the transition of our products to cloud offerings and the costs related to cloud operations; intense competition in our market; weakened global economic conditions may adversely affect the P&C insurance industry including the rate of information technology spending; and other factors detailed in Guidewire’s most recent Form 10-Q filed with the Securities and Exchange Commission. Guidewire undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Guidewire’s views as of any date subsequent to the date of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Diana Stott, Director, Communications
Guidewire Software
+1 650-356-4941 dstott@guidewire.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye